Analysts Anticipate Juno Therapeutics Inc (JUNO) Will Post Earnings of -$1.15 Per Share

Equities analysts expect that Juno Therapeutics Inc (NASDAQ:JUNO) will report ($1.15) earnings per share for the current quarter, according to Zacks. Five analysts have made estimates for Juno Therapeutics’ earnings. Juno Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 76.9%. The firm is expected to announce its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that Juno Therapeutics will report full year earnings of ($3.34) per share for the current year. For the next fiscal year, analysts expect that the business will post earnings of ($4.26) per share, with EPS estimates ranging from ($4.35) to ($4.17). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Juno Therapeutics.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. During the same period last year, the company earned ($0.57) EPS. The firm’s revenue for the quarter was up 115.4% compared to the same quarter last year.

JUNO has been the topic of several analyst reports. Raymond James Financial raised their price target on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 price target on shares of Juno Therapeutics in a research note on Friday, October 6th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. Wells Fargo & Co reaffirmed a “market perform” rating and set a $63.00 price target (up from $54.00) on shares of Juno Therapeutics in a research note on Wednesday. Finally, Citigroup reaffirmed a “buy” rating and set a $59.00 price target on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have given a buy rating to the company’s stock. Juno Therapeutics presently has a consensus rating of “Hold” and an average target price of $47.26.

In other news, EVP Robert Azelby sold 1,816 shares of the stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36. Following the transaction, the executive vice president now directly owns 70,832 shares in the company, valued at approximately $3,184,606.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Hans Edgar Bishop sold 270,250 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total transaction of $12,477,442.50. Following the transaction, the chief executive officer now owns 2,772,679 shares in the company, valued at $128,014,589.43. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 365,337 shares of company stock worth $17,540,499. Insiders own 15.08% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of JUNO. The Manufacturers Life Insurance Company raised its holdings in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Advisor Group Inc. raised its holdings in Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the period. QS Investors LLC purchased a new position in Juno Therapeutics in the second quarter valued at approximately $135,000. Bronfman E.L. Rothschild L.P. raised its holdings in Juno Therapeutics by 27,376.9% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in Juno Therapeutics in the fourth quarter valued at approximately $173,000. Hedge funds and other institutional investors own 69.94% of the company’s stock.

Juno Therapeutics (JUNO) traded down $3.56 during trading on Thursday, hitting $67.81. 5,229,618 shares of the company’s stock traded hands, compared to its average volume of 2,846,186. Juno Therapeutics has a one year low of $19.07 and a one year high of $74.35. The firm has a market cap of $7,742.07, a PE ratio of -20.06 and a beta of 2.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Juno Therapeutics Inc (JUNO) Will Post Earnings of -$1.15 Per Share” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/analysts-anticipate-juno-therapeutics-inc-juno-will-post-earnings-of-1-15-per-share.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Get a free copy of the Zacks research report on Juno Therapeutics (JUNO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply